FT-1101 is an inhibitor of all four BET family members that is structurally unique from other BET inhibitors in the JQ-1 class.276 Its potency against leukemia cell lines accelerated it into a phase I clinical trial to assess safety, PK, pharmacodynamics, and clinical activity in patients with R/R AML or NHL. The gene discussed is DNER; the disease is non-Hodgkin lymphoma.